Organization

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

6 abstracts

Abstract
A NOVEL, FULLY 3-DIMENSIONAL DYNAMIC CONTRAST MRI METHOD IN THE HAND REVEALS DETAILS OF SYNOVIAL INFLAMMATION AND PROVIDES A SENSITIVE MEASURE OF CHANGE
Org: Bioxydyn, Imorphics, Centre for Imaging Sciences, University of Manchester, Manchester, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Combined Rheumatology Practise, Sydney, Australia,
Abstract
ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS
Org: Nuffield Orthopaedic Centre, Oxford, United Kingdom, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States of america, St Vincent’s University Hospital and Conway institute for Biomolecular Research, University College Dublin, Dublin, Ireland, Division of Rheumatology allergy and Immunology, UC San Diego School of Medicine, La Jolla, CA, United States of america, Department of Dermatology, ICahn School of Medicine at Mt Sinai, New York, NY, United States of america,
Abstract
ASSESSMENT OF DISEASE ACTIVITY USING RAPID3 AND EVALUATION OF TREATMENT EFFECT OF GUSELKUMAB IN PATIENTS WITH PSA: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL
Org: Oregon Health and Science U, Portland, United States of america, Guy’s and St. Thomas NHS Foundation Trust, London, United Kingdom, Memorial University of Newfoundland, St. John’s, Canada, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Icahn School of Medicine at Mt Sinai, Dermatology, New York, United States of america,
Abstract
ANTI INFLAMMATORY EFFECT OF PDE5 INHIBITION: SCOPE FOR A NEW POTENTIAL INDICATION IN SSC ASSOCIATED MYOSITIS
Org: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, University of Rome Foro Italico, Rome, Italy, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, Sapienza University of Rome, Rome, Italy, Myriad RBM, Austin-TX, United States,
Abstract
BARICITINIB, AN ORAL JANUS KINASE (JAK)1/JAK2 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO CDMARD THERAPY: RESULTS OF THE PHASE 3 RA-BUILD STUDY
Org: Department of Rheumatology, Cochin Hospital, Paris, France, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Province of China, Desert Medical Advances, Palm Desert, United States, Veszprém Csolnoky Ferenc County Hospital, Vészprem, Hungary,